Francis Medical announced today that it has completed an oversubscribed $80 million Series C equity financing.

IceCure Medical’s ProSense® Cryoablation technology shows promise in treating kidney tumors with an 88.7% recurrence-free rate in patients unable to undergo surgery, based on interim results ...

Headlining the year’s developments were studies of catheter ablation and concomitant use of LAAO in patients with AF.

IceCure Medical (ICCM) announced interim results from the company’s ICESECRET study of cryoablation for patients with small renal masses who cannot be offered kidney preserving surgery.